An Operationally Seamless Phase 2/3, Randomized, Active-Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of GS-1720 in Combination With GS-4182 Versus Biktarvy in Treatment-Naive People With HIV-1

Date Added
December 30th, 2024
PRO Number
Pro00141056
Researcher
Eric Meissner

List of Studies


Keywords
HIV / AIDS
Summary

The main objective of this study is to test a once-weekly HIV medication regimen in persons who have not taken HIV treatment before. The goal is to see if taking a once a week pill combination (GS-1720 and GS-4182) works as well as taking a daily pill Biktarvy® (B/F/TAF). Participants will either take the weekly pill or continue with Biktarvy® for about 48 weeks or longer. The study will look at how well each option controls HIV levels.

Institution
MUSC
Recruitment Contact
Jamila Williams
(843) 792-1088
keithja@musc.edu



-- OR --